

# **Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Pipeline Review, H2 2018**

<https://marketpublishers.com/r/SB063DAA801EN.html>

Date: November 2018

Pages: 47

Price: US\$ 3,500.00 (Single User License)

ID: SB063DAA801EN

## **Abstracts**

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Pipeline Review, H2 2018

### **SUMMARY**

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report Serine/Threonine Protein Kinase Pim 1 - Pipeline Review, H2 2018, outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Proto-oncogene serine/threonine-protein kinase Pim-1 is an enzyme encoded by the PIM1 gene. It promotes cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression CDKN1B at both transcriptional and post-translational levels.

It mediates survival signaling through phosphorylation of BAD which induces release of the anti-apoptotic protein Bcl-X (L)/BCL2L1. It phosphorylation of MAP3K5, another proapoptotic protein by PIM1 significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis The molecules developed by

companies in Phase II, Preclinical and Discovery stages are 1, 7 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular and Immunology which include indications Prostate Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Chronic Lymphocytic Leukemia (CLL), Bladder Cancer, Diffuse Large B-Cell Lymphoma, Hematological Tumor, Lymphoma, Myocardial Infarction, Non-Small Cell Lung Carcinoma, Pancreatic Cancer, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Solid Tumor and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

Furthermore, this report also reviews key players involved in Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1)

The report reviews Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Serine/Threonine Protein Kinase Pim

1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) -  
Overview

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) -  
Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) -  
Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) -  
Companies Involved in Therapeutics Development

Incyte Corp

Inflection Biosciences Ltd

Jasco Pharmaceuticals LLC

Novartis AG

Sanofi

SARomics Biostructures AB

Tolero Pharmaceuticals Inc

Yakult Honsha Co Ltd

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) -  
Drug Profiles

Gene Therapy to Activate PIM1 for Myocardial Infarction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IBL-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCB-53914 - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress  
LGB-321 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
SBX-1501 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Small Molecule to Inhibit CSNK2 and PIM1 for Oncology - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Small Molecule to Inhibit PIM1 and PIM3 for Oncology - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Small Molecule to Inhibit PIM1, PIM2 and PIM3 for Solid Tumors and Hematological Tumors - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Small Molecules to Inhibit Pim Kinase for Pancreatic Cancer - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Small Molecules to Inhibit Pim-1 for Prostate Cancer - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Small Molecules to Inhibit PIM1 and PIM2 for Oncology - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
SMI-4a - Drug Profile  
Product Description  
Mechanism Of Action

R&D Progress

TP-3654 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) -

Dormant Products

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) -

Discontinued Products

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) -

Product Development Milestones

Featured News & Press Releases

Oct 23, 2017: Tolero Pharma To Present Preclinical Data Supporting Development of Cancer Drug Candidate TP-3654 for Myc-dependent Triple Negative Breast Cancer

Oct 05, 2017: Tolero Pharma to Deliver Keynote Presentations at 9th International Conference on Leukemia and Hematologic Oncology

Jun 30, 2014: Tolero's PIM Kinase Inhibitor Demonstrates Promising Activity in Preclinical Models of Urothelial Carcinoma

Apr 01, 2013: Jasco Pharma To Present Data On PIM Inhibitor Program At AACR Annual Meeting 2013

Mar 31, 2011: Jasco Pharma To Present Data On Preclinical PIM Inhibitor Program At AACR Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018  
Number of Products under Development by Therapy Areas, H2 2018  
Number of Products under Development by Indication, H2 2018  
Number of Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018 (Contd..1), H2 2018  
Number of Products under Investigation by Universities/Institutes, H2 2018  
Products under Investigation by Universities/Institutes, H2 2018  
Number of Products by Stage and Mechanism of Actions, H2 2018  
Number of Products by Stage and Route of Administration, H2 2018  
Number of Products by Stage and Molecule Type, H2 2018  
Pipeline by Incyte Corp, H2 2018  
Pipeline by Inflection Biosciences Ltd, H2 2018  
Pipeline by Jasco Pharmaceuticals LLC, H2 2018  
Pipeline by Novartis AG, H2 2018  
Pipeline by Sanofi, H2 2018  
Pipeline by SARomics Biostructures AB, H2 2018  
Pipeline by Tolero Pharmaceuticals Inc, H2 2018  
Pipeline by Yakult Honsha Co Ltd, H2 2018  
Dormant Products, H2 2018  
Dormant Products, H2 2018 (Contd..1), H2 2018  
Discontinued Products, H2 2018



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

### COMPANIES MENTIONED

Incyte Corp

Inflection Biosciences Ltd

Jasco Pharmaceuticals LLC

Novartis AG

Sanofi

SARomics Biostructures AB

Tolero Pharmaceuticals Inc

Yakult Honsha Co Ltd

## I would like to order

Product name: Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/SB063DAA801EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SB063DAA801EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

